As Biocryst Pharmaceuticals INC (BCRX) Market Value Declined, Dafna Capital Management LLC Boosted by $3.01 Million Its Stake

March 14, 2018 - By Maria Brooks

Investors sentiment increased to 1.69 in 2017 Q3. Its up 0.01, from 1.68 in 2017Q2. It is positive, as 12 investors sold BCRX shares while 24 reduced holdings. 28 funds opened positions while 33 raised stakes. 79.80 million shares or 20.47% more from 66.24 million shares in 2017Q2 were reported. Los Angeles Cap Management & Equity Rech accumulated 25,170 shares. Grp One Trading Limited Partnership holds 47,367 shares or 0% of its portfolio. Arrowmark Colorado Lc reported 12,019 shares stake. Great Point Lc holds 1.67% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 1.64 million shares. Blackrock owns 6.62M shares for 0% of their portfolio. Swiss Bancshares holds 171,300 shares or 0% of its portfolio. Baker Bros Advsr Lp reported 0.59% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Artal Sa accumulated 0.06% or 650,000 shares. Comml Bank Of Mellon, a New York-based fund reported 370,031 shares. Art Advisors Ltd Company accumulated 255,666 shares or 0.07% of the stock. Manufacturers Life Insur The owns 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 62,981 shares. Amalgamated Comml Bank holds 0% or 10,189 shares. Alps Advsr holds 79,203 shares or 0% of its portfolio. Jennison Associate Ltd Liability Com holds 0.02% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 3.08M shares. Citadel Ltd Limited Liability Company holds 0.01% or 1.40 million shares in its portfolio.

Since September 18, 2017, it had 0 insider purchases, and 1 insider sale for $294,035 activity.

Nathan Fischel increased its stake in Biocryst Pharmaceuticals Inc (BCRX) by 101.86% based on its latest 2017Q3 regulatory filing with the SEC. Dafna Capital Management Llc bought 602,100 shares as the company’s stock declined 16.46% while stock markets rallied. The hedge fund run by Nathan Fischel held 1.19M shares of the health care company at the end of 2017Q3, valued at $6.25 million, up from 591,128 at the end of the previous reported quarter. Dafna Capital Management Llc who had been investing in Biocryst Pharmaceuticals Inc for a number of months, seems to be bullish on the $529.57 million market cap company. The stock increased 0.94% or $0.05 during the last trading session, reaching $5.38. About 436,916 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since March 14, 2017 and is uptrending. It has outperformed by 58.38% the S&P500.

Dafna Capital Management Llc, which manages about $196.24M and $161.05 million US Long portfolio, decreased its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 41,500 shares to 262,121 shares, valued at $24.15 million in 2017Q3, according to the filing.

More important recent BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news were published by: which released: “BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy …” on February 27, 2018, also published article titled: “Biocryst Pharmaceuticals Inc (BCRX) Files 10-K for the Fiscal Year Ended on …”, published: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q4 2017 Results …” on February 28, 2018. More interesting news about BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was released by: and their article: “BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming …” with publication date: February 19, 2018.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals had 34 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 8. The company was maintained on Friday, May 26 by H.C. Wainwright. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Neutral” rating given on Tuesday, February 9 by JP Morgan. Jefferies upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Wednesday, January 6 to “Buy” rating. Noble Financial maintained the shares of BCRX in report on Tuesday, August 8 with “Buy” rating. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Overweight” rating given on Friday, August 12 by PiperJaffray. The rating was upgraded by JMP Securities to “Market Outperform” on Friday, December 16. The company was downgraded on Friday, October 9 by Bank of America. The rating was maintained by Jefferies on Friday, August 5 with “Hold”. FBR Capital maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday, February 9 with “Outperform” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.